Bristol Myers says actinium-225 therapy RYZ101 meets Phase 3 progression-free survival goal
The ACTION-1 interim analysis in neuroendocrine tumors after Lu-177 therapy disclosed no hazard ratio or medians; full data await a medical meeting.
- Nasdaq slides 2.9% as Intel has its worst day since the 1970s and chip stocks fall
- Intel shares fall 29%, their worst day since the 1970s, cutting about $12 billion from the US government's stake
- S&P revises Meta's outlook to negative over AI capital spending and negative free cash flow
- Mistral releases open weights for Mistral Large 4, its 1-trillion-parameter model
- Google's Suncatcher satellite returns the first AI response from a data-centre TPU in orbit
- Apple says Apple Intelligence features will reach China with iOS 27.3, using Alibaba's Qwen in Siri and Writing Tools
- Anthropic renames Claude Max 20x to Ultra and drops the 5-hour limit for verified Ultra accounts
- Google, Microsoft, OpenAI and Anthropic back a shared robots.txt signal for opting out of AI training